India  

Astra Zeneca gets nod for anticoagulant drug

IndiaTimes Saturday, 20 January 2024
AstraZeneca Pharma India announced that it has received approval from the Central Drugs Standard Control Organisation for the import and marketing of Andexanet Alfa. The therapy addresses life-threatening or refractory bleeding associated with the use of Factor Xa (FXa) inhibitors, says a company statement.FXa inhibitors are increasingly employed for preventing and treating thrombotic events, such as deep vein thrombosis and pulmonary embolism, as well as in patients at high risk of stroke due to atrial fibrillation. While these medications effectively prevent unwanted clot formation, they also elevate the risk of major bleeding, which can be life-threatening.
0
shares
ShareTweetSavePostSend
 

You Might Like


💡 newsR Knowledge: Other News Mentions

AstraZeneca AstraZeneca British pharmaceutical company

Dominica to honour PM for aid during pandemic

Indian Prime Minister Narendra Modi is set to receive Dominica's highest civilian award, the Dominica Award of Honour. The award recognizes Modi's contributions..
IndiaTimes

Central Drugs Standard Control Organisation Central Drugs Standard Control Organisation Indian Apex Drug Regulatory Body

Bring health supplements under drug control watch, suggests panel

An inter-ministerial committee has recommended that health supplements claiming to cure or mitigate diseases be classified as drugs. This shift aims to increase..
IndiaTimes

Related news from verified sources

Astra Zeneca gets nod for anticoagulant drug

AstraZeneca Pharma India announced that it has received approval from the Central Drugs Standard Control Organisation for the import and marketing of Andexanet...
IndiaTimes

Probe launced in Lee Sun Kyun's death

The Gyeonggi Southern Provincial Police Agency's Anti-Corruption and Economic Crime Investigation Unit has taken control of the investigation into the drug use...
IndiaTimes